MCID: CNT005
MIFTS: 57

Central Nervous System Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Central Nervous System Lymphoma

MalaCards integrated aliases for Central Nervous System Lymphoma:

Name: Central Nervous System Lymphoma 12 15 17
Primary Central Nervous System Lymphoma 74
Primary Cns Lymphoma 12
Cns Lymphoma 74
Microglioma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3234
ICD9CM 36 200.5
NCIt 51 C9301
SNOMED-CT 69 21964009 69110006

Summaries for Central Nervous System Lymphoma

Disease Ontology : 12 A hematologic cancer that has material basis in lymphoma located in central nervous system.

MalaCards based summary : Central Nervous System Lymphoma, also known as primary central nervous system lymphoma, is related to primary central nervous system lymphoma and intraocular lymphoma. An important gene associated with Central Nervous System Lymphoma is MYD88 (MYD88 Innate Immune Signal Transduction Adaptor), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Allograft rejection. The drugs leucovorin and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include b cells, brain and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Central Nervous System Lymphoma

Diseases in the Central Nervous System Lymphoma family:

Primary Central Nervous System Lymphoma

Diseases related to Central Nervous System Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 209)
# Related Disease Score Top Affiliating Genes
1 primary central nervous system lymphoma 34.2 BCL6 CD274 IL2 MGMT MYD88
2 intraocular lymphoma 32.8 BCL6 IL10
3 acquired immunodeficiency syndrome 30.8 BCL6 IL10 IL2 MYC
4 human immunodeficiency virus infectious disease 30.4 CXCL12 IL10 IL2
5 human immunodeficiency virus type 1 30.1 CD274 CXCL12 IL10 IL2
6 testicular lymphoma 30.0 BCL6 FOXP1 MYD88
7 macroglobulinemia 29.9 CXCL12 MYD88 TNFSF13B
8 lymphocytic leukemia 29.8 IL2 MYC MYD88
9 leukemia, chronic lymphocytic 29.7 BCL6 CXCL12 IL2 TNFSF13B
10 myasthenia gravis 29.7 IL10 IL2 TNFSF13B
11 diffuse large b-cell lymphoma 29.3 BCL6 FOXP1 MALT1 MYC MYD88 PRDM1
12 common variable immunodeficiency 29.1 IL10 IL2 TNFSF13B
13 lymphoma, non-hodgkin, familial 28.8 BCL6 CXCL12 IL2 MALT1 MYC TNFSF13B
14 myeloma, multiple 28.7 CDKN2A CXCL12 IL2 MYC PRDM1 TNFSF13B
15 lymphoma 11.4
16 aids - neurological complications 11.2
17 glioblastoma 10.6
18 reticulum cell sarcoma 10.6
19 glioblastoma multiforme 10.5
20 glioma 10.4
21 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.4 BCL6 MYC
22 primary cutaneous diffuse large b-cell lymphoma, leg type 10.3 CDKN2A MYD88
23 multiple sclerosis 10.3
24 anaplastic oligodendroglioma 10.3 CDKN2A MGMT
25 myasthenic syndrome, congenital, 14 10.3 CD274 MYC
26 lymphoepithelioma-like thymic carcinoma 10.3 CD274 CDKN2A
27 meningitis 10.3
28 encephalitis 10.3
29 colon lymphoma 10.3 BCL6 CDKN2A
30 retinitis pigmentosa 22 10.3 CDKN2A IL10
31 histiocytic sarcoma 10.2
32 nodal marginal zone b-cell lymphoma 10.2 BCL6 MALT1
33 central nervous system hematologic cancer 10.2 BCL6 IL10 MYD88
34 breast giant fibroadenoma 10.2 CDKN2A MGMT
35 systemic lupus erythematosus 10.2
36 hepatitis 10.2
37 lymphoproliferative syndrome 10.2
38 toxoplasmosis 10.2
39 megaesophagus 10.2 CDKN2A MYC
40 chromosomal triplication 10.2 BCL6 MALT1
41 gaucher disease, type ii 10.2 IL10 IL2
42 clonorchiasis 10.2 IL10 IL2
43 multicentric castleman disease 10.2 BCL6 IL10
44 diabetes insipidus 10.2
45 retinitis pigmentosa 44 10.2 IL10 IL2
46 balanoposthitis 10.2 CDKN2A IL2
47 paracoccidioidomycosis 10.1 IL10 IL2 MYD88
48 epstein-barr virus-associated gastric carcinoma 10.1 CD274 CDKN2A IL10
49 primary effusion lymphoma 10.1 BCL6 MYC
50 suppressor of tumorigenicity 3 10.1 CDKN2A MYC

Graphical network of the top 20 diseases related to Central Nervous System Lymphoma:



Diseases related to Central Nervous System Lymphoma

Symptoms & Phenotypes for Central Nervous System Lymphoma

GenomeRNAi Phenotypes related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

27 (show all 19)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-101 9.98 CD274
2 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.98 PRDM1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-12 9.98 CD274 MGMT PRDM1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.98 CD274 PRDM1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.98 PRDM1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.98 PRDM1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.98 PRDM1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.98 MGMT
9 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.98 CD274
10 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.98 CD274 PRDM1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.98 CD274
12 Increased shRNA abundance (Z-score > 2) GR00366-A-37 9.98 MGMT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-5 9.98 MGMT
14 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.98 PRDM1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.98 CD274
16 Increased shRNA abundance (Z-score > 2) GR00366-A-92 9.98 MGMT
17 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.98 PRDM1
18 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.36 CDKN2A IL10 IL2 MALT1 MYD88
19 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.36 CDKN2A IL10 IL2 MALT1 MYC MYD88

MGI Mouse Phenotypes related to Central Nervous System Lymphoma:

47 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.2 BCL6 CD274 CDKN2A CXCL12 IL10 IL2
2 immune system MP:0005387 10.17 BCL6 CD274 CDKN2A CXCL12 IL10 IL2
3 cellular MP:0005384 10.15 BCL6 CD274 CDKN2A CXCL12 IL10 IL2
4 cardiovascular system MP:0005385 10.11 BCL6 CDKN2A CXCL12 IL10 IL2 MYC
5 mortality/aging MP:0010768 10.11 BCL6 CD274 CDKN2A CXCL12 IL10 IL2
6 endocrine/exocrine gland MP:0005379 10.08 BCL6 CDKN2A IL10 IL2 MGMT MYC
7 liver/biliary system MP:0005370 9.95 BCL6 CDKN2A CXCL12 IL10 IL2 MYC
8 no phenotypic analysis MP:0003012 9.85 BCL6 CD274 CDKN2A CXCL12 IL10 IL2
9 muscle MP:0005369 9.8 BCL6 CDKN2A CXCL12 IL10 MYC PRDM1
10 neoplasm MP:0002006 9.8 CDKN2A IL10 IL2 MGMT MYC MYD88
11 reproductive system MP:0005389 9.56 BCL6 CDKN2A CXCL12 IL10 IL2 MYC
12 respiratory system MP:0005388 9.1 BCL6 CDKN2A IL10 IL2 MGMT MYD88

Drugs & Therapeutics for Central Nervous System Lymphoma

Drugs for Central Nervous System Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 269)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
leucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
2
Methotrexate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
3
Cytarabine Approved, Experimental, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 147-94-4, 65-46-3 6253
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1177-87-3
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-02-2 5743
6
Teniposide Approved Phase 4 29767-20-2 34698
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
8
Fotemustine Investigational Phase 4 92118-27-9
9 Folate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
10 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
14 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
16 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
17 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Vitamin B9 Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
19 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 BB 1101 Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
24
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
25
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
26
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
27
Ofloxacin Approved Phase 3 82419-36-1 4583
28
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
29
rituximab Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
30
Etoposide Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 33419-42-0 36462
31
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
32
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 85622-93-1 5394
33
Carmustine Approved, Investigational Phase 3,Phase 2 154-93-8 2578
34
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 38904 498142
35
Thiotepa Approved, Investigational Phase 3,Phase 2 52-24-4 5453
36
Dalteparin Approved Phase 3 9005-49-6
37
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
38
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
39
Ondansetron Approved Phase 3,Not Applicable 99614-02-5 4595
40
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
41
Amphotericin B Approved, Investigational Phase 3,Phase 1,Phase 2 1397-89-3 5280965 14956
42
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Not Applicable 93-14-1 3516
43
Dextromethorphan Approved Phase 3 125-71-3 5362449 5360696
44
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
45
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 68538-85-2
46
Idarubicin Approved Phase 2, Phase 3,Phase 3 58957-92-9 42890
47
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 3 55-98-1 2478
48
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
49
Mechlorethamine Approved, Investigational Phase 3,Phase 1,Phase 2 51-75-2 4033
50
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4

Interventional clinical trials:

(show top 50) (show all 182)
# Name Status NCT ID Phase Drugs
1 Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) Completed NCT00153530 Phase 4 methotrexate
2 Treatment of Primary CNS Lymphoma Recruiting NCT01960192 Phase 4 HD-MTX-Ara-C regimen;FVD regimen
3 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
4 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
5 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
6 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
7 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
8 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
9 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
10 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
11 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
12 Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy Recruiting NCT02657785 Phase 2, Phase 3 R-IDARAM plus intrathecal chemotherapy
13 Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL Recruiting NCT02836158 Phase 2, Phase 3 R-IDARAM plus intrathecal chemotherapy
14 BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT Recruiting NCT03733327 Phase 2, Phase 3 Busulfan (BU);Cyclophosphamide (CY);Etoposide (VP-16)
15 Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma Recruiting NCT02313389 Phase 3 Rituximab, Methotrexate, Temozolomide
16 High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma Recruiting NCT02531841 Phase 3 Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®);Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
17 MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma Unknown status NCT02399189 Phase 2 R-MT followed by auto-HSCT
18 a Phase II Study in Primary Central Nervous System Lymphoma Unknown status NCT00455286 Phase 2 Methotrexate;Methylprednisolone;Temozolomide
19 Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma Unknown status NCT02934204 Phase 2 methotrexate;temozolomide
20 Chemotherapy and Radiation Therapy in Treating Patients With HIV-Related Primary Central Nervous System Lymphoma Unknown status NCT00003261 Phase 2 methotrexate;zidovudine
21 Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma Unknown status NCT00942747 Phase 2 temsirolimus
22 Pemetrexed and Temozolomide in Treating Patients With Relapsed Primary Central Nervous System Lymphoma (PCNSL) Unknown status NCT01985451 Phase 2 Pemetrexe;Temozolomide
23 Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine Unknown status NCT00503594 Phase 2 Methotrexate and temozolomide;Methotrexate , procarbazine ,vincristine ,cytarabine
24 Temozolomide, Nedaplatin, Vincristine, and Radiotherapy as First-line Treatment in Newly Diagnosed Primary CNS Lymphoma Unknown status NCT01735747 Phase 2 nedaplatin;vincristine;Temozolomide
25 Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma Unknown status NCT00989352 Phase 2 Methotrexate;Lomustine;Procarbazine;Rituximab
26 High-Dose Sequential Chemoimmunotherapy for B-Cell Lymphomas With Central Nervous System Involvement Unknown status NCT00801216 Phase 2 High-dose sequential chemotherapy and autologous transplant
27 Combination Chemotherapy Plus Filgrastim in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma Unknown status NCT00032149 Phase 1, Phase 2 cyclophosphamide;etoposide;mitoxantrone hydrochloride;prednisolone;vincristine sulfate
28 Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer Unknown status NCT00387530 Phase 2 oral sodium phenylbutyrate;valganciclovir
29 PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma Completed NCT02669511 Phase 2 PQR309
30 Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma Completed NCT00193973 Phase 2 Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C
31 Zidovudine Plus Interleukin-2 and Ganciclovir in Treating Patients With AIDS-Related Primary Central Nervous System Lymphoma Completed NCT00006264 Phase 2 ganciclovir;zidovudine
32 Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma Completed NCT01011920 Phase 2 Methotrexate;Ara-C;Rituximab;Thiotepa;BCNU
33 Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) Completed NCT02301364 Phase 2 Buparlisib (BKM120)
34 Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma Completed NCT00210314 Phase 2 high dose methotrexate;high dose cytarabine
35 Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma Completed NCT00074191 Phase 2 cytarabine;dexamethasone;lomustine;methotrexate;procarbazine hydrochloride
36 Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma Completed NCT00074178 Phase 2 cyclophosphamide;cytarabine;dexamethasone;etoposide phosphate;methotrexate
37 Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma Completed NCT00068250 Phase 1, Phase 2 rituximab;methotrexate;temozolomide 100 mg/m^2;temozolomide 150 mg/m^2;temozolomide 200 mg/m^2;post-radiation therapy temozolomide
38 Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma Completed NCT00000801 Phase 2 Filgrastim;Vincristine sulfate;Doxorubicin hydrochloride;Cyclophosphamide;Cytarabine;Dexamethasone
39 High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study Completed NCT01083342 Phase 2 MTX, MVD, VIA
40 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Central Nervous System Lymphoma Completed NCT00003632 Phase 2 carmustine;cytarabine;etoposide;melphalan;methotrexate
41 Hydroxyurea in Treating Patients With Epstein-Barr Virus-Associated Primary CNS Lymphoma and AIDS Completed NCT00002940 Phase 2 hydroxyurea
42 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Primary CNS Lymphoma Completed NCT00003061 Phase 2 cytarabine;methotrexate
43 Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma Completed NCT00098774 Phase 2 cytarabine;etoposide;leucovorin calcium;methotrexate;temozolomide
44 Methotrexate and Thiotepa in Treating Patients With Newly Diagnosed Primary CNS Lymphoma Completed NCT00045539 Phase 2 leucovorin calcium;methotrexate;thiotepa
45 High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma Completed NCT01182415 Phase 2 High-dose chemotherapy
46 Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Completed NCT00727831 Phase 1, Phase 2 glucarpidase;leucovorin calcium;methotrexate
47 Interferon Alfa in Treating Children With HIV-Related Cancer Completed NCT00002621 Phase 2
48 A Study for Patients With Non-Hodgkin's Lymphomas Completed NCT00542919 Phase 2 enzastaurin
49 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
50 Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer Completed NCT00006225 Phase 1, Phase 2

Search NIH Clinical Center for Central Nervous System Lymphoma

Genetic Tests for Central Nervous System Lymphoma

Anatomical Context for Central Nervous System Lymphoma

MalaCards organs/tissues related to Central Nervous System Lymphoma:

42
B Cells, Brain, T Cells, Liver, Bone, Breast, Kidney

The Foundational Model of Anatomy Ontology organs/tissues related to Central Nervous System Lymphoma:

20
Central Nervous System

Publications for Central Nervous System Lymphoma

Articles related to Central Nervous System Lymphoma:

(show top 50) (show all 1092)
# Title Authors Year
1
Primary central nervous system lymphoma revealed by multiple intraventricular mass lesions. ( 30178179 )
2019
2
Primary central nervous system lymphoma with no enhancement initially and no significant progression over a long term: a case report and review of the literature. ( 30207801 )
2019
3
MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type. ( 30306208 )
2019
4
Intraocular involvement is associated with a high risk of disease relapse in primary central nervous system lymphoma. ( 30320386 )
2019
5
Genetic evidence implies that primary and relapsed tumors arise from common precursor cells in primary central nervous system lymphoma. ( 30353605 )
2019
6
(R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study. ( 30535802 )
2019
7
Post-transplant primary central nervous system lymphoma after Epstein-Barr virus cerebellitis. ( 30607891 )
2019
8
MicroRNA signature constituted of miR-30d, miR-93, and miR-181b is a promising prognostic marker in primary central nervous system lymphoma. ( 30615673 )
2019
9
Primary Central Nervous System Lymphoma: Molecular Pathogenesis and Advances in Treatment. ( 30616219 )
2019
10
MRI as a diagnostic biomarker for differentiating primary central nervous system lymphoma from glioblastoma: A systematic review and meta-analysis. ( 30637843 )
2019
11
Highly Active Antiretroviral Therapy and Gamma Knife Radiosurgery for the Treatment of AIDS-Related Primary Central Nervous System Lymphoma: A Case Report. ( 30654158 )
2019
12
High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: Data From the Japan Society for Hematopoietic Cell Transplantation Registry. ( 30664936 )
2019
13
A Rare Case of Primary Central Nervous System Lymphoma in an Adolescent Female Treated with High-Dose Methotrexate and Rituximab-Based Chemoimmunotherapy and Consolidation Whole Brain Radiotherapy. ( 30669145 )
2019
14
Hematopoietic stem cell transplantation in primary central nervous system lymphoma: a review of the literature. ( 30671909 )
2019
15
Bilateral vitritis as an initial presentation of primary central nervous system lymphoma. ( 30672490 )
2019
16
An 18-Year-Old Male With X-linked Lymphoproliferative Syndrome Type 1 Who Developed Primary Central Nervous System Lymphoma 6 Months After Primary Epstein-Barr Virus Infection. ( 30676439 )
2019
17
Diagnostic performance of DWI for differentiating primary central nervous system lymphoma from glioblastoma: a systematic review and meta-analysis. ( 30706241 )
2019
18
miR-370 Sensitizes TMZ Response Dependent of MGMT Status in Primary Central Nervous System Lymphoma. ( 30712191 )
2019
19
Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma. ( 30714128 )
2019
20
The role of ABCB1 polymorphism as a prognostic marker for primary central nervous system lymphoma. ( 30729282 )
2019
21
Differentiation of primary central nervous system lymphoma from high-grade glioma and brain metastasis using arterial spin labeling and dynamic contrast-enhanced magnetic resonance imaging. ( 30777220 )
2019
22
Magnetic resonance texture analysis utility in differentiating intraparenchymal neurosarcoidosis from primary central nervous system lymphoma: a preliminary analysis. ( 30789057 )
2019
23
Unusual Relapse of Primary Central Nervous System Lymphoma Both Inside and Outside Central Nervous System in Patient with Ventriculoperitoneal Shunt. ( 30794971 )
2019
24
High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China. ( 30821418 )
2019
25
A rare extrapyramidal manifestation in a patient with primary central nervous system lymphoma. ( 30860142 )
2019
26
Role of miRNA-21 in the diagnosis and prediction of treatment efficacy of primary central nervous system lymphoma. ( 30867786 )
2019
27
Permeability measurement using dynamic susceptibility contrast magnetic resonance imaging enhances differential diagnosis of primary central nervous system lymphoma from glioblastoma. ( 30877463 )
2019
28
A tale of two eras: the story of autologous stem cell transplantation with and without thiotepa for primary central nervous system lymphoma. ( 30878604 )
2019
29
Recurrent Epstein-Barr Virus-positive (EBV+) Primary Central Nervous System Lymphoma (PCNSL) in a Patient with Clinical Features of Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS). ( 30880301 )
2019
30
Primary central nervous system lymphoma in patients with and without HIV infection: a multicenter study and comparison with U.S national data. ( 30888569 )
2019
31
Comparative study on different therapies on patients with primary central nervous system lymphoma. ( 30899177 )
2019
32
Seizures in patents with primary central nervous system lymphoma: Prevalence and associated features. ( 30901566 )
2019
33
Surgical Resection for Primary Central Nervous System Lymphoma: A Systematic Review. ( 30904794 )
2019
34
Autologous Stem Cell Transplantation in Central Nervous System Lymphoma: A Multicenter Retrospective Series and a Review of the Literature. ( 30914301 )
2019
35
Primary central nervous system lymphoma mimicking cerebellopontine angle lesion. ( 30928235 )
2019
36
Difficult-to-treat Syndrome of Inappropriate Antidiuretic Hormone Secretion in a Patient with Secondary Central Nervous System Lymphoma. ( 30931179 )
2019
37
Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma. ( 30943052 )
2019
38
Radiomic features and multilayer perceptron network classifier: a robust MRI classification strategy for distinguishing glioblastoma from primary central nervous system lymphoma. ( 30952930 )
2019
39
Outcomes of Consecutively Diagnosed Primary Central Nervous System Lymphoma Patients Using the Alberta Lymphoma Clinical Practice Guideline Incorporating Thiotepa-Busulfan Conditioning for Transplantation-Eligible Patients. ( 30965138 )
2019
40
B-cell central nervous system lymphoma developing in a patient with cerebral meningioangiomatosis. ( 30976365 )
2019
41
Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma. ( 30989325 )
2019
42
Cell-type-specific sensitivity of bortezomib in the methotrexate-resistant primary central nervous system lymphoma cells. ( 30993483 )
2019
43
Diagnosis of central nervous system lymphoma via cerebrospinal fluid cytology: a case report. ( 31064334 )
2019
44
Evolving Treatments for Primary Central Nervous System Lymphoma. ( 31099614 )
2019
45
A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC network study. ( 31102405 )
2019
46
Primary central nervous system lymphoma of the optic chiasm. ( 31109502 )
2019
47
Craniotomy and Survival for Primary Central Nervous System Lymphoma. ( 29660011 )
2019
48
Machine Learning-based Texture Analysis of Contrast-enhanced MR Imaging to Differentiate between Glioblastoma and Primary Central Nervous System Lymphoma. ( 29769456 )
2019
49
The diagnostic role and dynamic changes in cerebrospinal fluid neopterin during treatment of patients with primary central nervous system lymphoma. ( 29982995 )
2018
50
Central Nervous System Lymphoma Harboring the JAK2 V617F Mutation That Developed after a 20-year History of Polycythemia Vera. ( 29984752 )
2018

Variations for Central Nervous System Lymphoma

Cosmic variations for Central Nervous System Lymphoma:

9 (show all 34)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM10656 TP53 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.742C>T p.R248W 17:7674221-7674221 0
2 COSM43448 TNFAIP3 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.2273C>G p.P758R 6:137881219-137881219 0
3 COSM5878666 TET2 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.4034A>C p.Y1345S 4:105261838-105261838 0
4 COSM4440707 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.596G>A p.S199N 3:177050103-177050103 0
5 COSM4440703 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1376G>A p.S459N 3:177033011-177033011 0
6 COSM4440696 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1256C>T p.S419F 3:177033131-177033131 0
7 COSM4440698 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1335G>T p.V445V 3:177033052-177033052 0
8 COSM4440709 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.148A>T p.I50F 3:177053829-177053829 0
9 COSM4440712 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.230C>T p.P77L 3:177051701-177051701 0
10 COSM4440706 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.637C>A p.H213N 3:177050062-177050062 0
11 COSM4440705 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1274G>T p.R425M 3:177033113-177033113 0
12 COSM4440713 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.229C>A p.P77T 3:177051702-177051702 0
13 COSM4440710 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.70T>C p.S24P 3:177053907-177053907 0
14 COSM4440704 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1336T>G p.Y446D 3:177033051-177033051 0
15 COSM4440697 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1255T>A p.S419T 3:177033132-177033132 0
16 COSM4440708 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.458G>A p.G153E 3:177050580-177050580 0
17 COSM4440695 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1261G>C p.D421H 3:177033126-177033126 0
18 COSM1716590 STAT5B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1924A>C p.N642H 17:42207711-42207711 0
19 COSM1155745 STAT3 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1981G>C p.D661H 17:42322402-42322402 0
20 COSM97163 PRDM1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.556+1G>C p.? 6:106099553-106099553 0
21 COSM97162 PRDM1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.183G>A p.I63Rfs*>19 6:106088449-106088449 0
22 COSM85940 MYD88 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.794T>C p.L265P 3:38141150-38141150 0
23 COSM517 KRAS haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.34G>A p.G12S 12:25245351-25245351 0
24 COSM306058 JAK3 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1533G>T p.M511I 19:17838299-17838299 0
25 COSM5878665 DNMT3A haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.2207G>T p.R736L 2:25240417-25240417 0
26 COSM144393 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.586T>A p.Y196N 17:63929439-63929439 0
27 COSM220733 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.587A>C p.Y196S 17:63929438-63929438 0
28 COSM220734 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.586T>C p.Y196H 17:63929439-63929439 0
29 COSM220736 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.587A>G p.Y196C 17:63929438-63929438 0
30 COSM5045028 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.591G>C p.E197D 17:63929434-63929434 0
31 COSM1737939 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.586T>G p.Y196D 17:63929439-63929439 0
32 COSM43455 CARD11 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.343T>C p.F115L 7:2945834-2945834 0
33 COSM43452 CARD11 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.343T>A p.F115I 7:2945834-2945834 0
34 COSM43451 CARD11 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1010G>A p.R337Q 7:2938686-2938686 0

Copy number variations for Central Nervous System Lymphoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 250739 9 21967751 21994490 Methylation deletion CDKN2A CNS lymphoma

Expression for Central Nervous System Lymphoma

Search GEO for disease gene expression data for Central Nervous System Lymphoma.

Pathways for Central Nervous System Lymphoma

Pathways related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.12 BCL6 IL10 IL2 MYC MYD88 TNFSF13B
2
Show member pathways
12.57 CXCL12 IL10 IL2 MALT1 TNFSF13B
3
Show member pathways
12.34 CXCL12 IL2 MALT1 MYD88 TNFSF13B
4
Show member pathways
12.12 CXCL12 IL10 IL2 MYC
5
Show member pathways
11.99 CXCL12 IL10 IL2 MYC
6 11.8 IL2 MYC TNFSF13B
7
Show member pathways
11.8 IL10 IL2 MALT1 MYD88
8 11.79 BCL6 CD274 CXCL12 IL10 IL2 MALT1
9 11.76 BCL6 CDKN2A MYC
10 11.74 BCL6 IL10 MYC
11 11.72 CDKN2A MGMT MYC
12 11.68 CXCL12 IL10 IL2
13
Show member pathways
11.57 CXCL12 IL10 IL2 MYC TNFSF13B
14 11.3 BCL6 IL10 PRDM1
15 11.26 CXCL12 MALT1 MYD88 TNFSF13B
16 11 IL10 IL2
17 10.92 CDKN2A MYC
18
Show member pathways
10.91 CDKN2A MYC
19 10.9 CXCL12 IL10 IL2 TNFSF13B

GO Terms for Central Nervous System Lymphoma

Biological processes related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.89 CXCL12 IL10 IL2 TNFSF13B
2 immune system process GO:0002376 9.89 BCL6 IL2 MYD88 PRDM1 TNFSF13B
3 positive regulation of gene expression GO:0010628 9.88 CDKN2A MYC MYD88 PRDM1
4 immune response GO:0006955 9.83 CD274 CXCL12 IL10 IL2 TNFSF13B
5 response to lipopolysaccharide GO:0032496 9.77 FOXP1 IL10 MYD88
6 response to ethanol GO:0045471 9.73 IL2 MGMT MYC
7 regulation of inflammatory response GO:0050727 9.63 BCL6 FOXP1 MYD88
8 negative regulation of cell-matrix adhesion GO:0001953 9.58 BCL6 CDKN2A
9 positive regulation of T cell proliferation GO:0042102 9.58 CD274 IL2 TNFSF13B
10 negative regulation of B cell proliferation GO:0030889 9.57 CDKN2A IL10
11 negative regulation of growth of symbiont in host GO:0044130 9.55 IL10 MYD88
12 cytokine-mediated signaling pathway GO:0019221 9.55 BCL6 IL10 IL2 MYC MYD88
13 positive regulation of interleukin-17 production GO:0032740 9.54 IL2 MYD88
14 positive regulation of smooth muscle cell proliferation GO:0048661 9.54 FOXP1 MYC MYD88
15 positive regulation of regulatory T cell differentiation GO:0045591 9.52 BCL6 IL2
16 response to molecule of bacterial origin GO:0002237 9.51 IL10 MALT1
17 regulation of tumor necrosis factor production GO:0032680 9.48 FOXP1 MYD88
18 positive regulation of B cell proliferation GO:0030890 9.43 BCL6 IL2 TNFSF13B
19 type 2 immune response GO:0042092 9.32 BCL6 IL10
20 negative regulation of apoptotic process GO:0043066 9.17 BCL6 IL10 IL2 MALT1 MGMT MYC
21 negative regulation of B cell apoptotic process GO:0002903 9.13 BCL6 FOXP1 IL2

Molecular functions related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.5 CXCL12 IL10 IL2
2 cytokine activity GO:0005125 9.26 CXCL12 IL10 IL2 TNFSF13B
3 kinase activator activity GO:0019209 9.16 IL2 MALT1
4 protein self-association GO:0043621 8.8 FOXP1 MALT1 MYD88
5 protein binding GO:0005515 10.07 BCL6 CD274 CDKN2A CXCL12 FOXP1 IL10

Sources for Central Nervous System Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....